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Background: Schizophrenia is a severe neuropsychiatric disorder that is hypothesized to result from disturbances in
early brain development. There is mounting evidence to support a role for developmentally regulated epigenetic
variation in the molecular etiology of the disorder. Here, we describe a systematic study of schizophrenia-associated
methylomic variation in the adult brain and its relationship to changes in DNA methylation across human fetal brain
development.
Results: We profile methylomic variation in matched prefrontal cortex and cerebellum brain tissue from
schizophrenia patients and controls, identifying disease-associated differential DNA methylation at multiple loci,
particularly in the prefrontal cortex, and confirming these differences in an independent set of adult brain samples.
Our data reveal discrete modules of co-methylated loci associated with schizophrenia that are enriched for genes
involved in neurodevelopmental processes and include loci implicated by genetic studies of the disorder. Methylomic
data from human fetal cortex samples, spanning 23 to 184 days post-conception, indicates that schizophrenia-associated
differentially methylated positions are significantly enriched for loci at which DNA methylation is dynamically altered
during human fetal brain development.
Conclusions: Our data support the hypothesis that schizophrenia has an important early neurodevelopmental
component, and suggest that epigenetic mechanisms may mediate these effects.Background
Schizophrenia is a severe neuropsychiatric disorder charac-
terized by episodic psychosis and altered cognitive function.
With a lifetime prevalence of approximately 1%, schizo-
phrenia contributes significantly to the global burden
of disease [1]. Although schizophrenia does not typically
manifest until late adolescence or early adulthood, evi-
dence from neuroimaging, neuropathology and epi-
demiological studies has led to its conceptualization as
a neurodevelopmental disorder, with etiological origins
before birth [2]. To date, however, the neurobiological
mechanisms underlying the disorder remain largely* Correspondence: j.mill@exeter.ac.uk
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unless otherwise stated.undefined, and molecular evidence for in utero disturbances
in schizophrenia is currently lacking.
Schizophrenia is known to have a substantial genetic
component, involving a large number of common variants
with individually small effects on risk for the disorder
[3], as well as rarer mutations [4] and copy number vari-
ants [5] of greater effect size. Of note, several of the
most robustly supported schizophrenia susceptibility genes
have known roles in early brain development and appear
to impact on schizophrenia risk during this period [6,7].
Epidemiological research suggests that prenatal environ-
mental insults are also important, with established associa-
tions between hypoxia [8], maternal infection [9], maternal
stress [10], and maternal malnutrition or famine [11] and
risk for developing schizophrenia. These observations have
led to a growing interest in the role of developmentally
regulated epigenetic variation in the molecular etiology of
schizophrenia [12]. The notion that epigenetic processesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recent methylomic studies of disease-discordant monozy-
gotic twins [13], clinical sample cohorts [14], and post-
mortem brain tissue [15].
Here, we describe a systematic study of schizophrenia-
associated methylomic variation in the adult brain and
its relationship to changes in DNA methylation during
human fetal brain development. We profiled DNA methy-
lation in matched prefrontal cortex (PFC) and cerebellum
brain tissue from schizophrenia patients and controls,
subsequently assessing disease-associated regions in
human fetal cortex samples spanning 23 to 184 days
post-conception. Our data support the hypothesis that
schizophrenia has an important early neurodevelop-
mental component, and suggest that epigenetic mecha-
nisms likely contribute to these disturbances.
Results and discussion
Identification of schizophrenia-associated differentially
methylated positions in the prefrontal cortex
Our ‘discovery’ cohort comprised PFC and cerebellum
samples from schizophrenia patients and matched (for
sex, age and sample quality markers (for example, pH))
control donors archived in the MRC London Brain BankTable 1 Schizophrenia-associated differentially methylated po
Probe ID Genomic position (hg19) Gene Gene region
cg26173173 chr8:144642813 GSDMD Body
cg24803255 chr13:114807060 RASA3 Body
cg00903099 chr7:154862441 HTR5A TSS200
cg08171022 chr11:70185278 PPFIA1 Body
cg02857643 chr17:48696108 CACNA1G Body
cg00236305 chr2:1796076 MYT1L Body
cg14966346 chr14:104152124 KLC1 Body
cg13079528 chr7:4027346 SDK1 Body
cg14429765 chr8:6492531 MCPH1 Body
cg08602214 chr8:22864392 RHOBTB2 Body
cg19735533 chr2:241196887 - -
cg09507608 chr22:29873338 - -
cg23844013 chr1:57383752 C8A 3' UTR
cg26578910 chr19:47204096 PRKD2 Body
cg21847368 chr13:113744010 MCF2L Body
cg03607729 chr16:25138698 LCMT1 Body
cg10248981 chr10:126157948 LHPP Body
cg03445663 chr2:242170236 HDLBP Body
cg15079231 chr3:42572745 VIPR1 Body
cg21341878 chr4:2278462 ZFYVE28 Body
cg04922803 chr12:104444418 GLT8D2 TSS1500
cg18857062 chr6:43276478 CRIP3 Body
Listed are all probes associated with schizophrenia (SZ) with FDR ≤0.1. The 100 topfor Neurodegenerative Diseases (LBBND; see Materials
and methods; Tables S1 and S2 in Additional file 1).
Genome-wide patterns of DNA methylation were quanti-
fied using the Illumina Infinium HumanMethylation450
BeadChip (450K array) (Illumina Inc., San Diego, CA,
USA), performing pre-processing, normalization and
stringent quality control as previously described [16]
(see Materials and methods; Table S3 in Additional file 1).
In total, data from 43 PFC (20 schizophrenia and 23
controls) and 44 cerebellum (21 schizophrenia and 23
controls) samples passed quality control metrics and
were used for analysis. The top-ranked differentially
methylated positions (DMPs) in each brain region are
shown in Tables S4 and S5 in Additional file 1. Most
notably, highly significant DMPs were identified in the
PFC (Table 1), with probes in four genes being signifi-
cantly associated with schizophrenia at a false discovery
rate (FDR) ≤0.05: GSDMD (cg26173173: control = 78.9 ± 3.0,
schizophrenia = 83.3 ± 1.3, FDR = 0.03); RASA3 (cg24803255:
control = 65.1 ± 4.7, schizophrenia = 56.4 ± 4.1, FDR = 0.03);
HTR5A (cg00903099: control = 11.5 ± 1.7, schizophrenia =
9.2 ± 1.2, FDR = 0.03); and PPFIA1 (cg08171022: control =
53.1 ± 3.2, schizophrenia = 47.6 ± 3.2, FDR = 0.03) (Figure 1A).
As epigenetic epidemiological research can be confoundedsitions in the prefrontal cortex
P-value FDR Mean SZ Mean control Beta difference
1.16E-07 0.03 0.83 0.79 0.04
1.25E-07 0.03 0.56 0.65 −0.09
2.40E-07 0.03 0.09 0.12 −0.02
2.85E-07 0.03 0.48 0.53 −0.05
1.63E-06 0.1 0.87 0.92 −0.05
1.75E-06 0.1 0.67 0.73 −0.06
2.51E-06 0.1 0.72 0.77 −0.05
2.75E-06 0.1 0.71 0.79 −0.08
2.79E-06 0.1 0.79 0.76 0.03
2.87E-06 0.1 0.69 0.75 −0.07
2.94E-06 0.1 0.76 0.81 −0.06
2.95E-06 0.1 0.56 0.62 −0.06
3.20E-06 0.1 0.82 0.79 0.03
3.47E-06 0.1 0.67 0.71 −0.04
3.70E-06 0.1 0.80 0.84 −0.03
4.19E-06 0.1 0.70 0.75 −0.04
4.32E-06 0.1 0.55 0.63 −0.07
4.59E-06 0.1 0.51 0.59 −0.08
4.93E-06 0.1 0.76 0.80 −0.04
5.14E-06 0.1 0.75 0.81 −0.05
5.19E-06 0.1 0.68 0.62 0.06
5.29E-06 0.1 0.21 0.26 −0.04
-ranked DMPs are listed in Table S4 in Additional file 1.
Figure 1 Schizophrenia-associated DNA methylation differences in the prefrontal cortex. (A) Probes associated with four genes are significantly associated with schizophrenia at FDR ≤0.05: GSDMD
(control = 78.9 ± 3.0, schizophrenia = 83.3 ± 1.3, FDR = 0.03); RASA3 (control = 65.1 ± 4.7, schizophrenia = 56.4 ± 4.1, FDR = 0.03); HTR5A (control = 11.5 ± 1.7, schizophrenia = 9.2 ± 1.2, FDR = 0.03); and PPFIA1
(control = 53.1 ± 3.2, schizophrenia = 47.6 ± 3.2, FDR = 0.03). (B) The top-ranked differentially methylated region is located in an intergenic CpG island in NRN1 where there is coordinated hypomethylation
across 29 adjacent CpG sites in schizophrenia patients (red) compared with controls (blue). The mean DNA methylation difference across all 29 sites is -1.77% (FDR = 3.1e-2), with a notable region of
hypomethylation (-3.7%) spanning three consecutive DMPs (FDR = 2.4e-2). (C) Selected schizophrenia-associated DMPs were successfully validated and replicated. Shown are technical validation data for the
CpG site corresponding to probe cg24803255 in RASA3 confirming significant schizophrenia-associated hypomethylation (control = 70.5 ± 3.7, schizophrenia = 66.4 ± 3.2, P = 0.0002). Additional technical
validation data for other loci are shown in Figure S2 in Additional file 1. Also shown are replication data for cg24803255 in RASA3 in PFC from the Montreal cohort confirming significant schizophrenia-
associated hypomethylation (control = 65.1 ± 5.5, schizophrenia = 61.3 ± 4.7, P = 0.05). (D) DNA methylation differences at the 100 top-ranked PFC DMPs identified in the London discovery cohort are
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rithm to assess the extent to which DMPs are influenced
by differences in neuronal proportions between individ-
uals [19]. Notably, all top-ranked PFC DMPs remained
significantly associated with schizophrenia after correction
for the estimated neuronal proportion in each sample
(Table S4 in Additional file 1). In contrast to the PFC, few
schizophrenia-associated DMPs (none at FDR ≤0.05) were
identified in the cerebellum (Table S5 in Additional file 1),
suggesting that disease-associated epigenetic differences
are likely to be brain region-specific.
Region-based analysis of altered DNA methylation in
schizophrenia
As DNA methylation is often correlated across adjacent
CpG sites [20,21], we used the Illumina Methylation Ana-
lyser (IMA) [22] package to aggregate and assess DNA
methylation across adjacent probes within annotated re-
gions of the genome. Again, we observe widespread evi-
dence for schizophrenia-associated DNA methylation
differences, occurring specifically in the PFC (Figure S1
and Table S6 in Additional file 1). Most notably we ob-
serve a large (approximately 8 kb) region spanning the
gene body of the Neuritin 1 (NRN1) gene across which
29 adjacent CpG sites are consistently hypomethylated
in schizophrenia patients compared with controls
(Figure 1B). The mean DNA methylation difference across
all 29 sites is -1.77% (FDR = 3.1e-2), with a notable region
of hypomethylation (-3.7%) spanning three consecutive
DMPs (FDR = 2.4e-2). This is of particular interest be-
cause NRN1 plays a well-established role in neurodevelop-
ment and synaptic plasticity [23], and genetic variation in
the gene has been linked to cognitive phenotypes in
schizophrenia [24].
Validation and replication of schizophrenia-associated
DNA methylation differences in the prefrontal cortex
To confirm the array data, bisulfite-pyrosequencing
was used to validate schizophrenia-associated DMPs in
the vicinity of three genes (NRN1 (cg00565348), C8A
(cg23844013), and RASA3 (cg24803255)) in the same
samples. Bisulfite-PCR amplification was performed in
duplicate using the primers and assay conditions in
Table S7 in Additional file 1. Fully methylated and fully
unmethylated control samples were included in all ex-
periments. For each amplicon we confirmed significant
DNA methylation differences in the same direction as
reported by the 450K array (Figure 1C; Figure S2 and
Table S8 in Additional file 1). We subsequently generated
a replication PFC (BA9) 450K dataset using schizophrenia
and control brains archived at the Douglas Bell-Canada
Brain Bank, Montreal, Canada (n = 33, 18 schizophrenia
and 15 controls; Tables S9 and S10 in Additional file 1)
using the Illumina 450K array as described above.Strikingly, DNA methylation differences at the top-ranked
PFC DMPs identified in the ‘LBBND’ cohort (listed in
Table S11 in Additional file 1) were strongly correlated
with schizophrenia-associated differences at the same
probes in PFC tissue from the Montreal replication samples
(r = 0.54, P = 6.8e-09) with a consistent direction of effect
observed across both cohorts and significant differences ob-
served for top-ranked DMPs (Figure 1C,D).Evidence for schizophrenia-associated gene co-methylated
modules in the prefrontal cortex
We next employed weighted gene co-methylation network
analysis (WGCNA) to undertake a systems-level view of
the DNA methylation differences associated with schi-
zophrenia in the PFC [25,26]. Using probe-wise DNA
methylation data we identified 110 modules (representing
discrete networks of co-methylated sites), and the first
principal component of each individual module (termed
the ‘eigengene’) was used to assess the relationship with
disease status. Twelve PFC modules were significantly
associated with schizophrenia, most notably the ‘black’
(n = 6,647 probes, r = -0.52, P = 0.0004) and ‘pink’ mod-
ules (n = 4,399 probes, r = -0.45, P = 0.002) (Figure 2A).
Module membership in both modules is strongly correlated
with probe-level disease significance (black module:
r =0.39, P <1e-200; pink module: r = 0.22, P = 2.4e-49)
(Figure 2B). Repeating WGCNA on the cerebellum data
yielded no schizophrenia-associated modules, provid-
ing further evidence of brain region-specific DNA
methylation differences in schizophrenia. Furthermore, a
comparison of modules across the two brain regions
showed that while a subset of 43 PFC modules correlated
strongly (r >0.8) with 51 cerebellum modules, none of the
PFC schizophrenia-associated modules were correlated
with modules in the cerebellum. Finally, despite the low
number of samples and lack of power for replicating
WGCNA associations in the Montreal replication dataset,
the modular structure of DNA methylation in the PFC
was found to be strongly preserved across both brain co-
horts (Figure S3 in Additional file 1), with both the black
and pink modules being highly conserved and negatively
correlated with schizophrenia (black module: r = -0.26;
pink module: r = -0.10).Schizophrenia-associated co-methylated modules are
enriched for neurodevelopmental pathways and loci
previously implicated in the disorder
To test whether the identified schizophrenia-associated
modules were biologically meaningful, pathway and gene
ontology analyses were performed using Ingenuity Path-
way Analysis (IPA) and EASE (DAVID) software [28].
Enrichment for specific pathways and biological func-
tions was determined relative to the relevant microarray
Figure 2 Schizophrenia-associated gene co-methylation modules in the prefrontal cortex. (A) Heatmap representing correlations between module eigenvalues (ME) and clinical/demographic variables.
Each row represents a specific module, indicated by an arbitrary module color labeled on the y-axis. Dark red indicates strong positive correlation, dark green indicates strong negative correlation, and white
indicates no correlation, as indicated in color scale bar. P-values are given in parentheses. The black (P = 0.0004) and pink (P = 0.002) WGCNA modules are most significantly associated with schizophrenia in
the PFC. (B) Module membership in both modules is strongly correlated with probe significance with disease (black module: r = 0.39, P <1e-200; pink module: r = 0.22, P = 2.4e-49). (C) Ingenuity Pathway
Analysis of genes associated with CpG sites in the black module reveals a highly significant enrichment of disease pathways related to schizophrenia and other neuropsychiatric disease. (D) Co-methylation
networks between the top 1% of loci in the black and pink modules ranked by their module membership, where thicker lines indicate more connected genes. Black edges represent co-methylation between
probes in the black module and pink edges represent co-methylation in the pink module; thicker and deeper colored edges indicate stronger correlations between probes. Interestingly, the two modules are
connected by SHANK2, which encodes a molecular scaffold protein that plays a role in synaptogenesis. Furthermore, several of the genes are associated with schizophrenia in recent collaborative genome-















Figure 3 Schizophrenia associated DMPs are enriched for CpG sites undergoing epigenetic changes during fetal neocortex brain
development. (A) Correlation between DNA methylation and neurodevelopmental age (days post-conception) for 98 of the 100 top-ranked
schizophrenia-associated DMPs (blue) with corresponding FDR values (red). Dashed lines demarcate DMPs with FDR <0.01. (B) Distribution of the
number of CpG sites significantly associated with neocortex brain development (FDR <0.05) using 10,000 permutations of 98 randomly selected
CpG sites. The red arrow represents the number of significant (FDR <0.05) age-correlated CpG sites (n = 44) among the 100 top-ranked
schizophrenia-associated DMPs. (C,D) A CpG site in MYT1L, for example, significantly hypomethylated in schizophrenia (P = 0.00000175) (C) is
highly correlated with neocortical development (FDR = 1.39e-13) (D). Blue points represent male samples and pink points represent female samples.
Other examples of schizophrenia-associated DMPs correlated with neocortical development are shown in Figure S6 and Table S13 in Additional file 1.
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associated with CpG sites in the top-ranked PFC modules
reveals a highly significant enrichment of disease pathways
related to ‘schizophrenia and other neuropsychiatric dis-
orders’ in the black module (P = 3.67e-15 to 1.27e-03;
Figure 2C), and ‘nervous system development and func-
tion’ in both the black (P = 3.80e-18 to 1.37e-03; Figure
S4 in Additional file 1) and pink (P = 4.04e-15 to 3.16e-
03; Figure S5 in Additional file 1) modules. Consistent
with the IPA results, gene ontology analysis using EASE
(DAVID) [28] shows that both modules are significantlyenriched for functions related to nervous system and
neuron development, synaptic transmission and calcium
ion binding (Table S12 in Additional file 1). An analysis of
co-methylation networks between the top-ranked ‘hub’
probes in the black and pink modules shows that they are
connected by DNA methylation in the vicinity of SHANK2,
a molecular scaffold protein that plays a critical role in neu-
rodevelopment and synaptogenesis, and has been widely
implicated in several neurodevelopmental disorders, includ-
ing schizophrenia [29] (Figure 2D). Furthermore, several
of the probes are located in genes that have been strongly
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genome-wide association study (GWAS; for example,
CACNA1C, TSNARE1, PITPNM2, and HLA-L) [27].Schizophrenia-associated DMPs are enriched for CpG sites
undergoing epigenetic changes during fetal neocortex
brain development
Given previous evidence for a neurodevelopmental basis
to schizophrenia [2], and our analyses demonstrating an
enrichment of neurodevelopmental pathways involved in
disease, we next investigated whether schizophrenia-
associated DMPs are enriched for CpG sites undergoing
dynamic DNA methylation changes during human fetal
brain development. For each of the top-ranked PFC
DMPs we assessed the correlation between DNA methy-
lation and days post-conception in a 450K DNA methy-
lation dataset generated by our lab using human fetal
brain tissue (n = 179, range = 23 to 184 days post-
conception, number of matching 450K probes in fetal data-
set after quality control and filtering = 98/100; HH Spiers et
al., in preparation). Strikingly, DNA methylation at 44% of
the schizophrenia-associated DMPs is significantly associ-
ated (at FDR <0.05) with post-conception age in the devel-
oping fetal brain (Figure 3A), reflecting a highly
significant enrichment for neurodevelopmental DMPs
(10,000 permutations, P = 8e-04) amongst schizophrenia-
associated loci (Figure 3B) and reinforcing the notion that
neurodevelopmental dysfunction is involved in schizophre-
nia. For example, one of the top-ranked schizophrenia-
associated DMPs (cg00236305), located in the gene body of
MYT1L, is significantly hypomethylated (P = 1.75e-6) in pa-
tients compared with controls (Figure 3C). MYT1L encodes
a potent transcription factor integral to neurodevelopment
[30], and the same probe is highly correlated with neocor-
tical development (FDR = 1.39e-13; Figure 3D). Other
examples of schizophrenia-associated DMPs strongly
correlated with neocortical development are shown in
Figure S6 and Table S13 in Additional file 1.Conclusions
In this study we have found schizophrenia-associated vari-
ation in DNA methylation in the PFC, and identified
discrete modules of co-methylated loci associated with the
disorder that are significantly enriched for genes involved
in neurodevelopmental processes. Methylomic profiling
in human fetal cortex samples confirmed that disease-
associated DMPs are significantly enriched for loci at
which DNA methylation is dynamically altered during
human fetal brain development. These data strongly
support the hypothesis that schizophrenia has an important
early neurodevelopmental component, and suggest that epi-
genetic mechanisms may mediate the relationship between
neurodevelopmental disturbances and risk of disease.Materials and methods
Samples and sample processing
London Brain Bank for Neurodegenerative Disorders
PFC and cerebellum samples were obtained from 47 brains
archived in the LBBND. Subjects were approached in life
for written consent for brain banking, and all tissue dona-
tions were collected and stored following legal and ethical
guidelines (NHS reference number 08/MRE09/38; the
HTA license number for the LBBND brain bank is 12293).
The study is also approved by the University of Exeter
Medical School Research Ethics Committee (reference
number 13/02/009). Samples were dissected by a trained
neuropathologist, snap-frozen and stored at -80°C. Schizo-
phrenia patients were diagnosed by trained psychiatrists
according to Diagnostic and Statistical Manual of Mental
Disorders (DSM) criteria. Demographic information
for the samples is summarized in Tables S1 and S2 in
Additional file 1. Samples were randomized with respect
to gender and disease status to avoid batch effects
throughout all experimental procedures. Genomic DNA
was isolated using a standard phenol-chloroform extrac-
tion protocol. DNA was tested for degradation and purity
using spectrophotometry and gel electrophoresis.Douglas Bell-Canada Brain Bank, Montreal
PFC samples from 18 schizophrenia cases and 15 controls
were obtained from the Douglas Bell-Canada Brain
Bank (DBCBB) [31]. Brain specimens used in this study
were collected postmortem following consent obtained
with next of kin, according to tissue banking practices
regulated by the Quebec Health Research Fund [32], and
based on the OECD Guidelines on Human Biobanks and
Genetic Research Databases [33]. Samples were dissected
by neuropathology technicians, snap-frozen and stored at
-80°C. Psychiatric diagnoses were based on best-estimate
diagnostic procedures, following SCID I diagnostic interviews
conducted with informants, as described elsewhere [34].
Demographic information for the DBCBB samples is sum-
marized in Tables S8 and S9 in Additional file 1. Genomic
DNA was isolated using a standard phenol-chloroform
extraction protocol. DNA was tested for degradation and
purity using spectrophotometry and gel electrophoresis.Genome-wide quantification of DNA methylation
Microarray processing
DNA (500 ng) from each sample was treated with sodium
bisulfite in duplicate, using the EZ-96 DNA methylation kit
(Zymo Research, Irvine, CA, USA). DNA methylation was
quantified using the Illumina Infinium HumanMethyla-
tion450 BeadChip (Illumina Inc.) run on an Illumina HiS-
can System (Illumina) using the manufacturers’ standard
protocol.
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Signal intensities for each probe were extracted using Illu-
mina GenomeStudio software and imported into R [35]
using the methylumi and minfi packages [36,37]. Multi-
dimensional scaling plots of variable probes on the sex
chromosomes were used to check that the predicted
gender corresponded with the reported gender for each
individual. One sample showed a discrepancy between
measured and reported sex and was subsequently iden-
tified as having an XXY karyotype and removed from
the current study for independent investigation [38].
Comparison of non-CpG SNP probes on the array con-
firmed that matched PFC and cerebellum tissues were
sourced from the same individual. Raw beta values of
probes within brain region-specific DMRs (extracted
from [39]) were used to confirm the tissue identity of
each sample. Probes containing a SNP with minor allele
frequency >5% within 10 bp of the single base extension
site based on Illumina’s database and probes identified
by Chen and colleagues [40] (n = 34,548) were removed
from all analyses. Further data quality control and pro-
cessing steps were conducted using the wateRmelon
package [16] in R. The pfilter function was used to filter
data by beadcount and detection P-value. Samples with >1%
probes with a detection P-value >0.05 were removed
(PFC: n = 3 samples; cerebellum: n = 1 sample). Probes
with a detection P-value >0.05 in at least 1% of samples
and/or a beadcount <3 in 5% of samples were removed
across all samples to stringently control for poor quality
probes. Quality control sample exclusions are summa-
rized in Table S3 in Additional file 1. The dasen func-
tion was used to normalize the data as previously
described [16], with probes on the sex chromosomes re-
moved from all subsequent analysis.
Statistical analysis
First, analyses were performed to test for DNA methyla-
tion differences between schizophrenia cases and controls
at the individual probe level. To model the effect of
sample-specific variables we performed linear regression
for each probe using age, gender and disease status as
independent variables. Regression tests were performed
using the Limma [41] package in R, and prior to ana-
lyses β-values were log-transformed to M-values to im-
prove sensitivity. P-values were adjusted for multiple
testing according to the FDR procedure of Benjamini-
Hochberg. The CETS package in R [19] was used to
check that our top-ranked DMPs were not mediated by
the effect of differential neuronal cell proportions across
samples. To identify DMRs we used the Illumina Methyla-
tion Analyzer (IMA) [22] package to compute region-level
summaries of DNA methylation in the PFC and cerebel-
lum, which were then tested for association with disease
using Limma. P-values were adjusted for multiple testingaccording to the FDR procedure of Benjamini-Hochberg.
Significant DMRs were selected at a 5% FDR and visual-
ized using RCircos [42] and Gviz [43] packages. To investi-
gate whether schizophrenia-associated DMPs are enriched
for sites undergoing epigenetic changes during neurodeve-
lopment, we used an unpublished 450K DNA methylation
dataset of fetal cortex brain samples (n = 179, range 23 to
184 days post-conception) collected as part of ongoing
work in our group (HH Spiers et al., in preparation). For
the top 100 schizophrenia-associated DMPs in our dataset,
we extracted β-values of 98 matched probes in the neuro-
developmental dataset (n = 2 probes removed during qual-
ity control of fetal dataset). We then used Pearson’s
correlation tests to assess the number of probes show-
ing a significant relationship (FDR <0.05) between DNA
methylation and days post-conception. To evaluate the
genome-wide significance of this result we compared
the above correlation with an estimated null distribution
from 10,000 randomizations of the data. On each
randomization we randomly selected 98 probes and
computed the number of probes with FDR <0.05, as
described above. One-tail significance was assessed by
comparing the original number of significant probes
(FDR <0.05) to the estimated null distribution.
Bisulfite-pyrosequencing
Independent verification analysis was performed on three
PFC schizophrenia-associated DMPs (in the vicinity of
NRN1, C8A, and RASA3), based on results from both
the probe-wise and region-level analysis. Pyrosequencing
assays were designed using the PyroMark Assay design
software (Qiagen, Hilden, Germany). Bisulfite-PCR ampli-
fication was performed in duplicate using the primers and
assay conditions in Table S7 in Additional file 1. Fully
methylated and fully unmethylated control samples were
included in all experiments.
Replication analysis
DNA samples from the Montreal cohort were analyzed
using the Illumina Infinium HumanMethylation450
BeadChip using the same processing and quality control
steps as described above. For the top 100 schizophrenia-
associated DMPs in the LBBND cohort (Table S4 in
Additional file 1), we extracted β-values for matched probes
in the Montreal dataset. Pearson’s correlation was used to
assess the relationship between disease-associated DNA
methylation differences in the two datasets at these probes.
Weighted gene co-methylation network analysis
Network analysis was performed on normalized probe-
wise DNA methylation data (PFC: n = 445,617 probes;
cerebellum: n = 440,836 probes) using WGCNA [26].
For each brain region pair-wise correlations were used
to identify modules of highly co-methylated probes,
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network was created with a soft threshold parameter of 6
using the blockwiseModules function based on a block size
of 20,000. Each module was then labeled with a unique
color name. The first principle component of the methyla-
tion matrix of each module was calculated to give a ‘mod-
ule eigengene’ (ME) for each module (a weighted average
methylation profile). To identify modules associated with
schizophrenia, each of the ME values was regressed on dis-
ease status, in addition to other sample-specific variables:
pH, age, gender, brain weight and cerebellum weight. To
test whether the identified schizophrenia-associated mod-
ules were biologically meaningful, pathway and gene ontol-
ogy analyses were performed using IPA [44] and EASE
(DAVID) [28,45]. Correlations were performed between
the ME and DNA methylation values to calculate the mod-
ule membership of each probe (the extent to which a given
probe contributes to the ME). This module membership
value was used to identify the ‘hub’ genes in each module.
The function modulePreservation in the WGCNA package
was used to calculate module preservation statistics for the
Montreal PFC data based on the PFC modules built from
the discovery dataset.
Accession numbers
The Gene Expression Omnibus accession numbers for
the 450K array data reported in this paper are GSE61431
(LBBND dataset) and GSE61380 (DBCBB dataset).
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